Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -110.78M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 23,600
Avg Vol 30,360
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 64%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Phone: 919 313 9633
Address:
2525 East North Carolina Highway 54, Durham, United States
Latest News on HUMAW
Humacyte reports Q1 EPS (9c), consensus (12c)

2026-05-13T13:00:50.000Z - 2 hours ago

Humacyte reports Q1 EPS (9c), consensus (12c)


Humacyte Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 hours ago

Humacyte Earnings Call Transcript: Q1 2026


Humacyte names Todd Rasmussen chief surgical officer

2026-05-12T15:32:56.000Z - 1 day ago

Humacyte names Todd Rasmussen chief surgical officer


Humacyte Transcript: KOL event

Apr 28, 2026, 8:00 AM EDT - 15 days ago

Humacyte Transcript: KOL event


Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Apr 22, 2026, 8:00 AM EDT - 21 days ago

Humacyte Appoints Jim Mercadante as Chief Commercial Officer


Humacyte price target lowered to $1.50 from $3.50 at Barclays

2026-04-08T09:30:25.000Z - 5 weeks ago

Humacyte price target lowered to $1.50 from $3.50 at Barclays


Humacyte downgraded to Speculative Buy from Buy at Benchmark

2026-03-31T13:30:42.000Z - 6 weeks ago

Humacyte downgraded to Speculative Buy from Buy at Benchmark


Humacyte price target lowered to $1 from $3.50 at TD Cowen

2026-03-30T12:05:04.000Z - 6 weeks ago

Humacyte price target lowered to $1 from $3.50 at TD Cowen


Humacyte price target lowered to $1 from $3 at Piper Sandler

2026-03-30T11:58:53.000Z - 6 weeks ago

Humacyte price target lowered to $1 from $3 at Piper Sandler


Humacyte Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 6 weeks ago

Humacyte Earnings Call Transcript: Q4 2025


Humacyte reports Q4 EPS (13c), consensus (14c)

2026-03-27T11:22:11.000Z - 6 weeks ago

Humacyte reports Q4 EPS (13c), consensus (14c)


Humacyte prices $20M registered direct offering

2026-03-19T12:36:23.000Z - 7 weeks ago

Humacyte prices $20M registered direct offering


Humacyte receives Symvess purchase commitment

2026-03-19T12:36:11.000Z - 7 weeks ago

Humacyte receives Symvess purchase commitment


Humacyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 2 months ago

Humacyte Transcript: TD Cowen 46th Annual Health Care Conference


Humacyte To Participate in Upcoming Investor Conferences

Mar 2, 2026, 8:00 AM EST - 2 months ago

Humacyte To Participate in Upcoming Investor Conferences


Humacyte Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 6 months ago

Humacyte Earnings Call Transcript: Q3 2025


Humacyte Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 9 months ago

Humacyte Earnings Call Transcript: Q2 2025


Humacyte Earnings Call Transcript: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q1 2025


Humacyte Earnings Call Transcript: Q4 2024

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q4 2024


Humacyte Transcript: Investor Update

Mar 6, 2025, 12:00 PM EST - 1 year ago

Humacyte Transcript: Investor Update


Trestle Bio Announces Research Collaboration with Humacyte

Mar 6, 2025, 8:00 AM EST - 1 year ago

Trestle Bio Announces Research Collaboration with Humacyte